Analysts have revised their price target for Travelzoo downward from $25.25 to $22.25. They cited softer-than-expected Q3 results and lowered growth projections for 2025, although expectations for 2026 remain positive.
Analyst Commentary
Analysts have provided a mix of optimistic and cautious insights following Travelzoo's latest performance and updated forecasts.
Bullish Takeaways- Bullish analysts continue to maintain positive ratings on Travelzoo, even as price targets have recently been revised downward.
- Subscriber growth is expected to be a significant driver of stronger performance in 2026.
- There is continued confidence in Travelzoo’s longer-term growth prospects, with expectations of a recovery beyond the current year’s volatility.
- The core business model and consumer engagement strategies are considered supportive of future valuation improvements.
- Bearish analysts point to softer than expected Q3 results, which have resulted in immediate reductions in price targets.
- Concerns remain regarding execution risks, especially in relation to meeting 2025 forecasts.
- Revised projections suggest more modest growth in the near term, affecting sentiment and valuation.
- Changes to longer-term forecasts highlight ongoing competitive and operational headwinds expected in 2025.
What's in the News
- Noble Capital lowered its price target for Travelzoo to $21 from $26. The firm maintained an Outperform rating and cited a downwardly revised 2026 forecast after softer Q3 results (Noble Capital).
- Travelzoo released new Club Offers for UK Club Members, including discounted stays at a Yorkshire manor, a luxury hotel in Portugal’s Douro Valley, a ski trip in the French Alps, a 5-star countryside retreat in Spain, and London West End show and dinner packages (Travelzoo announcement).
- Travelzoo launched new Club Offers for U.S. members, featuring savings on Portugal vacations with flights, Bali trips, Hawaii two-island getaways, hotel stays under $99, and half-off nationwide spa treatments (Travelzoo announcement).
- Travelzoo completed the repurchase of 1,000,000 shares for $14.55 million, representing 8.61% of shares outstanding as part of its ongoing buyback program (Travelzoo announcement).
- Travelzoo provided updated earnings guidance and projected continued and accelerating revenue growth through 2025 and beyond, with increasing profitability as recurring membership fees are recognized (Travelzoo guidance).
Valuation Changes
- Consensus Analyst Price Target has decreased from $25.25 to $22.25, reflecting a more cautious outlook.
- Discount Rate has risen slightly from 8.12% to 8.47%, signaling an increase in perceived investment risk.
- Revenue Growth projection has fallen significantly from 10.84% to 7.02%, indicating tempered expectations for top-line expansion in the near term.
- Net Profit Margin has decreased from 14.99% to 10.17%, suggesting expectations for lower profitability.
- Future P/E has increased from 14.24x to 25.32x. This may indicate a valuation premium despite reduced growth and profit forecasts.
Have other thoughts on Travelzoo?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.